Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
SPJ-Saudi Pharmaceutical Journal. 2008; 16 (2): 135-145
em Inglês | IMEMR | ID: emr-99312

RESUMO

This research work describes the synthesis of some pyrazole and pyrazoline fused ring systems substituted with variable biologically-active chemical species. All of the newly synthesized target compounds were selected by the NCI for in-vitro antitumor screening. Six compounds namely, 3, 4a,b, 5a,b and 9a have passed successfully through the primary 3-cell line assay and were promoted for the full panel 60-cell line assay. These active compounds exhibited broad spectrum of antitumor activity against most of the tested tumor cell lines. Compound 5a proved to be the most active antitumor agent in the present study with GI[50], TGI and LC[50] MG-MID values of 8.12, 25.7 and 69.2 microM, respectively, with high sensitivity towards some leukemia, melanoma and renal cell lines. The other five active compounds showed variable degrees of appreciable antitumor activity [GI[50] and TGI MG-MID values range 14.1-19.5 and 38.0-53.7 micro M, respectively]


Assuntos
Pirazóis , Antineoplásicos , Avaliação de Medicamentos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA